INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS: Ten-Year Follow-Up.

Anti-VEGF Therapy for Ocular Histoplasmosis-Associated Choroidal Neovascularization: A Long-Term Follow-Up

We are embarking on a journey into the realm of ophthalmology, exploring the long-term efficacy of anti-vascular endothelial growth factor (VEGF) therapy for treating choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS). This study investigates the effectiveness of intravitreal anti-VEGF injections (IVI) alone or in combination with verteporfin photodynamic therapy (IVI/PDT) over a decade-long follow-up period. The researchers sought to determine the long-term outcomes of these treatments and assess their impact on visual acuity and treatment burden.

Anti-VEGF Therapy: A Promising Strategy for Long-Term CNV Management

The study, a retrospective analysis of 82 eyes from 74 patients, found that both IVI and IVI/PDT were effective in managing CNV associated with POHS. The combination therapy (IVI/PDT) was associated with a lower number of annual injections and a longer treatment-free interval. These findings suggest that anti-VEGF therapy, particularly when combined with PDT, can be a valuable tool for managing CNV in patients with POHS.

A Beacon of Hope for Patients with Ocular Histoplasmosis

This research provides valuable insights into the long-term management of CNV associated with POHS. The study's findings offer hope for patients with this condition, suggesting that anti-VEGF therapy can effectively manage CNV and preserve vision over an extended period. The research also highlights the potential benefits of combining IVI with PDT to reduce treatment burden and improve long-term outcomes.

Dr. Camel's Conclusion

This study provides a long-term perspective on the efficacy of anti-VEGF therapy for managing CNV associated with POHS. The findings suggest that both IVI and IVI/PDT can effectively manage CNV and preserve vision, with the combination therapy offering potential benefits in terms of reduced treatment burden. Remember, my dear colleagues, the desert of ophthalmological research is vast and constantly evolving, and we must always be prepared to embrace new discoveries and refine our approach to patient care!